A study has assessed the effect of introducing a microtablet dose dispenser and adjusting doses based on the monitoring of motor symptoms in people with Parkinson's Disease. Forms of L-dopa are usually limited to certain doses and are consequently not adaptable to needs. A microtablet dose dispenser enables more precise doses of L-dopa.
Daytime doses of L-dopa were replaced with L-dopa / carbidopa microtablets, 5mg / 1.25 mg delivered from a dose dispenser device with programmable reminders. After two weeks, doses were adjusted based on ambulatory accelerometry and clinical monitoring. The daily L-dopa dose was increased by 15% from period 1 to 2, and the dose interval was reduced by 12% .
The MDS-UPDRS parts II and III, disease-specific quality of life (PDQ-8), wearing-off symptoms (WOQ-19), and nonmotor symptoms (NMS Quest) improved after dose increases. Evaluation of accelerometry results demonstrated improvement in 60% of subjects and worsening in 25% of them.
The introduction of an L-dopa microtablet dispenser and accelerometry aided dose adjustments Parkinson’s Disease improve symptoms and quality of life in the short term.
Reference : CNS Neuroscience and Therapeutics [2018] 24 (5) : 439-447 (D.Jan Johansson, A.Ericsson, A.Johansson, A.Medvedev, D.Nyholm, F.Ohlsson, M.Senek, J.Spira, I.Thomas, J.Westin, F.Bergquist)
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/29652438
http://www.viartis.net/parkinsons.disease/news/180425.pdf
No comments:
Post a Comment